Follow us on Twitter
twitter icon@FreshPatents


Histidine patents

      

This page is updated frequently with new Histidine-related patent applications.




 Valuable-metal extraction method patent thumbnailValuable-metal extraction method
In order to selectively extract copper and/or lead from an acidic solution containing high concentrations of manganese, etc., the valuable-metal extracting agent of the present invention is expressed by general formula (1). In the formula, r1 and r2 each represent the same or different alkyl groups, r3 represents a hydrogen atom or an alkyl group, and r4 represents a hydrogen atom or a given group, other than an amino group, that bonds with an α carbon as an amino acid.
Sumitomo Metal Mining Co., Ltd.


 Short peptides and a  use as an antioxidant patent thumbnailShort peptides and a use as an antioxidant
A short chain polypeptide having antioxidant activity is provided. The short chain polypeptide has 2 to 4 amino acids bonded to form a polypeptide chain having an amine-terminal end and a carboxyl terminal end; wherein a net charge of the short chain polypeptide is positive, the amino terminal amino acid is an amino acid selected from the group consisting of arginine, lysine and histidine, the polypeptide chain following from the amino terminus comprises a hydrophobic or neutral amino acid, and the polypeptide chain is free of an amino acid having a negatively charged side-chain group.
L'oreal


 Purification of multi-specific receptors patent thumbnailPurification of multi-specific receptors
Also disclosed is a method for treatment, amelioration or prophylaxis of a disease selected from the group consisting of phenylketonuria (pku, følling's disease), hyperphenylalaninemia (hpa), alcaptonuria (black urine disease), tyrosinemia, hypertyrosinemia, myasthenia gravis, histidinemia, urocanic aciduria, maple syrup urine disease (msud), isovaleric acidemia (isovaleryl-coa dehydrogenase deficiency), homocystinuria, propionic acidemia, methylmalonic acidemia, and glutaric aciduria type 1 (ga-1), galactosemia, comprising administering to the gastrointestinal tract of a patient in need thereof an effective amount of a composition of molecular imprinted polymers (mips), said composition being capable of binding a symptom provoking agent of said disease.. .

 Aqueous liquid composition including high concentration of l-histidine patent thumbnailAqueous liquid composition including high concentration of l-histidine
Aqueous liquid compositions containing histidine at a high concentration, which is preferable for oral ingestion, are useful for the production of foods, drinks, pharmaceutical products, and the like. Particular aqueous liquid compositions contain histidine at a concentration greater than 20 wt % and may further contain a divalent or higher valent organic acid..
Ajinomoto Co., Inc.


 Tetrapeptides and a  use as an antioxidant patent thumbnailTetrapeptides and a use as an antioxidant
A tetrapeptide having antioxidant activity is provided. The tetrapeptide has a structure comprising, in amino acid sequence from n-terminus to c-terminus: tryptophan-x-tyrosine-x; wherein x is arginine, lysine, histidine or any positively-charged amino acid derivative such as 5-hydroxylysine, ornithine, 2,4-diamino-butyrate and 2,3-diamino-propionate.
L'oreal


 Functionalization and purification of molecules by reversible group exchange patent thumbnailFunctionalization and purification of molecules by reversible group exchange
Embodiments of the present disclosure include methods and compositions for functionalizing molecules, such as oligonucleotides, with functional groups, including polyhistidine tags useful in affinity methods. Some embodiments include methods for modifying and purifying complex mixtures of molecules by exchange of functional tags..
Illumina, Inc.


 Phosphohistidine analogs patent thumbnailPhosphohistidine analogs
And the hapten containing the residue of same. It also relates to the hapten conjugated to a carrier molecule and the isolated antibodies raised against the immunogens, said antibodies recognizing polypeptide containing a phosphorylated histidine or the phosphotriazole residue but it does not recognize an amino acid or polypeptide that is not phosphorylated or a polypeptide which is phosphorylated on amino acids other than histidine but not on histidine..

 Nanocomplex containing cationic peptide for biomolecule delivery patent thumbnailNanocomplex containing cationic peptide for biomolecule delivery
The present invention relates to developing an optimally efficient arginine-histidine-cysteine based peptide comprising nanocomplex that can deliver biomolecules across varied cell lines without any oxidative procedure through formation of monodisperse nanoparticles with sizes ranging between 50 and 110 nm.. .
Council Of Scientific And Industrial Research


 Specific internalization of nanoparticles into protein cages patent thumbnailSpecific internalization of nanoparticles into protein cages
The invention relates to a method to encapsulate nanoparticles into a protein cage by inserting the nanoparticles into the core through holes. Currently commercially available nanoparticles can be functionalized using the inventive method.
Nanyang Technological University


 Nickel extraction method patent thumbnailNickel extraction method
In the present invention, nickel is selectively extracted from an acidic solution that contains a high concentration of manganese. This valuable metal extraction agent is represented by the general formula.
Sumitomo Metal Mining Co., Ltd.


Monolith-based pseudo-bioaffinity purification methods for factor viii and applications thereof

The present disclosure relates to purification of factor viii protein and/or its fragments from various sources by employing monolith based pseudobioaffinity purification methods. In particular, l-histidine over cim monolith [histidine ligand affinity chromatography (hlac)] is used for the purification of wild-type factor viii from plasma cryoprecipitate, recombinant b-domain deleted factor viii (rbdd-fviii) expressed in various host systems and recombinant factor viii light chain expressed in pichia pastoris.
Centre For Bioseparation Technology - Vit

Histidinylated cationic amphiphiles, process for preparation therof and their liposomal formulation

Novel anti-cancer reagents capable of combating various types of tumors continue to be major research focus in many leading pharmaceutical companies round the globe. To this end, the present invention discloses processes for preparing a novel series of histidinylated cationic amphiphiles of formula i.
Council Of Scientific & Industrial Research

Composition for long-acting peptide analogs

The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: a-(cm)x-peptide (seq id no: 76), wherein a is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidiodacetic acid group, or 4) a moiety of formula (zyhisw)p (seq id no: 50), wherein z is any amino acid residue other than histidine, his is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if a has alkyl group with 6 to 36 carbon units x is greater than 0; and cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or n-arginine or n-lysine, wherein x is an integer between 0-6 and n may be any amino acid or none.
Pharmain Corporation

Method of inhibiting copper deposition on hair

A method of inhibiting copper deposition on hair and facilitating the removal of copper deposited on hair including applying to the hair a shampoo composition having ethylenediamine-n,n′-disuccinic acid (edds) and/or histidine, rinsing the shampoo composition from the hair, applying to the hair a conditioner composition comprising histidine, rinsing the conditioner composition from the hair, and applying to the hair a leave-on treatment comprising ethylenediamine-n,n′-disuccinic acid (edds).. .
The Procter & Gamble Company

Novel oral forms of a phosphonic acid derivative

Novel solution complexes of zoledronic acid are described which give rise to improved properties of zoledronic acid. The invention includes aqueous solution and molecular complexes of zoledronic acid with and optical isomers of asparagine, histidine, arginine and proline as well as pharmaceutical complexes containing them and methods of treatment using them..
Thar Pharmaceuticals, Inc.

Shampoo composition comprising gel matrix and histidine

A shampoo composition having from about 0.025% to about 0.25% histidine, by weight of the shampoo composition; from about 2% to about 50% of one or more detersive surfactants, by weight of the shampoo composition; and a gel matrix having from about 0.1% to about 20% of one or more fatty alcohols, by weight of the gel matrix; from about 0.1% to about 10% of one or more gel matrix surfactants, by weight of the gel matrix; and from about 20% to about 95% of an aqueous carrier, by weight of the gel matrix.. .
The Procter & Gamble Company

Method of inhibiting copper deposition on hair

A method of inhibiting copper deposition on hair and facilitating the removal of copper deposited on hair including applying to the hair a shampoo composition having histidine, rinsing the shampoo composition from the hair, applying to the hair a conditioner composition comprising histidine, and rinsing the conditioner composition from the hair.. .
The Procter & Gamble Company

Bioactive peptide complexes

Where: x1 is absent or contains not less than 1 amino acid; r1 and r2 peptide chains, containing amino acid residues, his or cys, interactable with transition metal ions, with r1 containing up to 5 amino acid residues or absent; r2 contains up to 3 amino acid residues or absent. histidine-rich peptide complexes, primarily alloferon family peptides with zn ions, will make it possible to create drugs with targeted mechanism of action, and design them with regard to understanding of drug target structure..

Treatment for chronic kidney disease

A method of treating chronic kidney disease by administering to a subject a composition that includes l-arginine, glycine, l-glutamine, l-histidine, l-aspartic acid l-glutamic acid, and l-carnosine.. .
Bio Health Solutions, Llc

Stabilized antibody-containing formulations

The present invention relates to antibody-containing lyophilized formulations free from reducing sugars, non-reducing sugars, sugar alcohols or polysaccharides as excipients and including one or more amino acid selected from the group consisting of arginine, histidine, lysine, serine, proline, glycine, alanine and threonine or a salt thereof.. .

Long-acting single-chain insulin analogues

A single-chain insulin analogue containing a basic side chain at position a8 (arginine, histidine, lysine, or ornithine), a basic side chain at position b29 (arginine, histidine, lysine, or ornithine), and a foreshortened c-domain of length 6-11 residues is provided. Residues c1 and c2 of the c-domain have a net negative charge of −1 or −2; c3 is chosen from a group consisting of gly, ala, pro, or ser; and the remaining c-domain segment is successively derived from the c-domain of igf-ii (rrsr, srrsr, vsrrsr, rvsrrsr, or srvsrrsr; seq id no: 13).
Case Western Reserve University

Pro-pigmenting peptides

The invention is directed to the use of at least one peptide of formula: x-(xaa1)n-pro*-(xaa2)m-y (i) with: —n=0, or 2; —m=0 or land if m=0 then n≠0 —xaa is: —an hydrophobic aminoacid selected from alanine (ala, a), valine (val, v), methionine (met, m), leucine (leu, l), isoleucine (ile, i), phenylalanine (phe, f), proline (pro, p) and analogues and derivatives thereof; —a polar aminoacid selected from serine (ser, s), threonine (thr, t), tyrosine (tyr, y), asparagine (asn, n), glutamine (gln, q) and analogues and derivatives thereof; or —glycine (gly, g); when n=2 the two aminoacids xaa1 can be the same or different; —xaa2 is: —an hydrophobic aminoacid selected from alanine (ala, a), valine (val, v), methionine (met, m), leucine (leu, l), isoleucine (ile, i), phenylalanine (phe, f), proline (pro, p) and analogues and derivatives thereof; —a basic aminoacid selected from arginine (arg, r), lysine (lys, k) and histidine (his, h) and analogues and derivatives thereof; —glycine (gly, g) or serine (ser, s); —at the n terminal end of the peptide, x is selected from h, —co—r1 and —so2—r1; —at the c terminal end of the peptide, y is selected from oh, or1, nh2, nhr1 or nr1r2, —r1 and r2 being independently from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group, that can be linear, branched, cyclic, poly-cyclic, non-saturated, hydroxylated, carbonylated, phosphorylated and/or sulphured, with the possibility to have in said group skeleton a o, s and/or n heteroatom; —pro* corresponding to a proline, an analogue or derivative thereof; excluding the peptides where x=h and y=oh, for a non therapeutical cosmetic pro-pigmenting treatment of skin. The invention also encompasses new tripeptides of formula (i) suitable for a non therapeutical cosmetic treatment of skin..
Sederma

Use of chromium histidinate for treatment of cardiometabolic disorders

Provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising chromium and histidine, chromium histidinate complexes, or combinations thereof, to the individual.. .
Jds Therapeutics, Llc

Indium extraction agent and indium extraction method

Provided are an extraction agent and extraction method that selectively extract and, at a low cost, recover indium from an acidic solution containing indium and zinc. The indium extraction agent comprises an amide derivative represented by general formula (i).
Sumitomo Metal Mining Co., Ltd.

Flavour additives

The present invention relates to the use of one or more nucleotides selected from the group consisting of gmp (guanosine monophosphate) and imp (inosine monophosphate), a first amino acid selected from the group consisting of alanine, histidine and glycine or a mixture thereof; a second amino acid selected from the group consisting of proline and threonine or a mixture thereof; and furaneol for increasing the palatability of a foodstuff to a companion animal. The invention also relates to a pet foodstuff or supplement comprising one or more nucleotides selected from the group consisting of gmp and imp, a first amino acid selected from the group consisting of alanine, histidine and glycine or a mixture thereof; a second amino acid selected from the group consisting of proline and threonine or a mixture thereof; and furaneol, and also to a method of increasing the palatability of a foodstuff to a companion animal..
Mars Incorporated

Flavour additives

The present invention relates to the use of a first amino acid selected from the group consisting of glycine, alanine, cysteine, histidine, leucine, methionine, phenylalanine, serine, tryptophan and tyrosine or a mixture of two or more thereof; a second amino acid selected from the group consisting of aspartic acid, cystine, glutamic acid, glutamine, isoleucine, lysine, aspartic acid, ornithine, threonine, valine, proline and hydroxyproline or a mixture of two or more thereof and one or more furanones for increasing the palatability of a foodstuff to a companion animal. The invention also relates to a pet foodstuff or supplement comprising a first amino acid selected from the group consisting of glycine, alanine, cysteine, histidine, leucine, methionine, phenylalanine, serine, tryptophan and tyrosine or a mixture of two or more thereof; a second amino acid selected from the group consisting of aspartic acid, cystine, glutamic acid, glutamine, isoleucine, lysine, aspartic acid, ornithine, threonine, valine, proline and hydroxyproline or a mixture of two or more thereof and one or more furanones, and also to a method of increasing the palatability of a foodstuff to a companion animal..
Mars, Incorporated

Flavour additives

The present invention relates to the use of one or more nucleotides, one or more amino acids selected from the group consisting of glycine, asparagine, alanine, cysteine, histidine, leucine, methionine, phenylalanine, serine, tryptophan and tyrosine and one or more furanones for increasing the palatability of a foodstuff to a companion animal. The invention also relates to a pet food—stuff or supplement comprising one or more nucleotides, one or more amino acids selected from the group consisting of glycine, asparagine, alanine, cysteine, histidine, leucine, methionine, phenylalanine, serine, tryptophan and tyrosine and one or more furanones, and also to a method of increasing the palatability of a foodstuff to a companion animal..
Mars Incorporated

Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same

A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.
Regeneron Pharmaceuticals, Inc.

Amadoriase having altered substrate specificity

This invention provides an amadoriase having high substrate specificity to fructosyl valyl histidine. Such amadoriase comprises substitution of one or more amino acid residues at positions corresponding to amino acids selected from the group consisting of position 98, position 259, position 154, position 125, position 261, position 263, position 106, position 103, position 355, position 96, position 66, position 67, position 70, position 100, position 110, position 113, position 114, and position 156 in the amadoriase derived from the genus coniochaeta.
Kikkoman Corporation

Method for isolating valuable metal

Provided is a method that selectively extracts and, at a low cost, recovers indium from an acidic solution containing indium and gallium. The present invention is a method that is for isolating a valuable metal and that, by means of subjecting an acidic solution containing indium and gallium to a solvent extraction that is by means of an extraction agent comprising an amide derivative represented by a general formula, extracts indium from the acidic solution.
Sumitomo Metal Mining Co., Ltd.

Nutritional composition for improving heart failure

The present invention provides a nutritional composition for improving a patient with heart failure; the nutritional composition is consisting of therapeutically effective high amounts of leucine and histidine. The present invention also provides the nutritional supplement comprising the nutritional composition, which may be a beverage product, a dietary supplement or food.
Chang Gung Memorial Hospital, Keelung

Method for preparing exenatide

Disclosed in the present invention is a method for preparing exenatide. Serine resin is obtained through a first coupling of serine and resin and successively with amino acids through a second coupling to obtain a peptide resin with a sequence as shown by seq id no.
Hybio Pharmaceutical Co., Ltd.

Ergothioneine production through metabolic engineering

The present disclosure relates to the production of ergothioneine through either in vitro enzymatic transformations or fermentations using microbials created by metabolic engineering. Also disclosed are transformed cells useful in such methods and ergothioneine produced by such methods.

Polymeric conjugates of c-1 inhibitors

Polymer conjugates containing a c1-inhibitor having at least one substantially non-antigenic polymer covalently attached to the c1-inhibitor via amino group of the c1 inhibitor are provided. In the polymer conjugates, the substantially non-antigenic polymer is attached to the n-terminal of c1-inhibitor.
Belrose Pharma, Inc.

Novel flavour compositions with improved flavour and/or flavour shelf-life

The present invention relates to a novel flavour composition for modulating the flavour of a nutritional product, comprising a mixture of a single amino acid and wet alkane polyol, wherein the single amino acid is selected from the group consisting of ornithine, lysine, glycine, alanine, monosodium glutamate, histidine, threonine, phenylalanine, tyrosine, serine, methionine, arginine, glutamic acid and cysteine. The invention also concerning the use of such a flavour composition for modulating the flavor and/or flavour shelf-life of a nutritional product, the process for preparing such a flavour composition and a nutritional product comprising such a flavour composition..
Nestec S.a.

Gallium extraction agent and gallium extraction method

Provided are an extraction agent and extraction method that selectively extract and, at a low cost, recover gallium from an acidic solution containing gallium and zinc. The gallium extraction agent comprises an amide derivative represented by general formula (1).
Sumitomo Metal Mining Co., Ltd.

Method for producing an l-amino acid using a bacterium of the enterobacteriaceae family

A method for producing an l-amino acid is described, for example l-threonine, l-lysine, l-histidine, l-phenylalanine, l-arginine, l-tryptophan, or l-glutamic acid, using a bacterium of the enterobacteriaceae family, wherein the bacterium has been modified to enhance an activity of a wild-type alcohol dehydrogenase encoded by the adhe gene or a mutant alcohol dehydrogenase which is resistant to aerobic inactivation.. .
Ajinomoto Co., Inc.

Protein hydrolysate

The present invention relates to a protein hydrolysate, wherein the hydrolysate has a percentage of peptides having a histidine residue at the c-terminal end of at least 10 wt % of the total peptide content of the protein hydrolysate and a process for preparing the protein hydrolysate. The invention further relates to a food or feed product comprising the protein hydrolysate..
Dsm Ip Assets B.v.

Antibody formulations

The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain ii of her2 (for example, pertuzumab), and a formulation comprising an antibody that binds to dr5 (for example, apomab).. .
Genentech, Inc.

New protecting compositions for recombinantly produced factor vii

A histidine-free composition comprising: a high purity factor viii (r-factor viii); arginine and/or sucrose; a surface-active agent to prevent or at least inhibit surface adsorption of factor viii; an amount of calcium chloride for specific stabilization of factor viii.. .
Octapharma Ag

Cosmetic and pharmaceutical composition with modified olygopeptides in form of supramolecular assembly

The invention is a cosmetic and pharmaceutical liposomal composition which comprises a mixture of carboxylated oligopeptides derived from natural polypeptides; insulin; hyaluronidase and collagenase by their enzymatic hydrolysis; followed by a carboxylation of the free amino groups of lysine, histidine, and additional hydrolysis of terminal amino groups in the oligopeptides. Natural polypeptides may be hydrolyzed with a proteolytic enzyme to form a mixture of oligopeptides and succinylated them.

Vaccine

The present invention relates to a vaccine comprising at least one peptide consisting of 7 to 19 amino acid residues consisting of the amino acid sequence (x3)mkdx2qlgx1 (seq id no. 99), wherein x1 is an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, threonine, tyrosine and valine, x2 is an amino acid residue selected from the group consisting of alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tyrosine and valine.
Affiris Ag

Methods of predicting and decreasing the risk of pre-term birth

Provided are methods for predicting the risk of pre-term birth in a pregnant subject, for identifying a subject having an increased risk of pre-term birth, for selecting a subject for participation in a clinical study, and for decreasing the risk of pre-term birth in a subject. These methods include providing a sample from the subject and detecting the level of one or more of growth arrest-specific protein 1 (gasi), alli-fused gene from chromosome 4 protein (ar4)/fragile x mental retardation 2 (fmr2) family member 3 (aff3), transthyretin (ttr), ryanodine receptor 1 (ryri), e26 transformation specific variant 6 (etv6), claudin-10, zinc finger protein 23 (znf23), collagen type xxvii α1 (col27ai), kazrin isoform-1, keratin-associated protein 10-9 (krtapio-9), huntingtin (htt), microtubule associated protein 9 (map9), coiled-coil domain-containing protein 13 (ccdc13), inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase isoform 2 (hisppdi), immunoglobulin gamma-3 chain c (ig-hg3), cysteine- and histidine-rich protein-1 (cyhri), and xp 002348181..
University Of Louisville Research Foundation, Inc.

Mutant neq hs dna polymerase derived from nanoarchaeum equitans and its application to hot-start pcr

A dna polymerase (neq dna polymerase) derived from nanoarchaeum equitans is split into neq l and neq s fragments, each of which contains inteins. A neq hot-start (hs) dna polymerase in which the inteins of the neq l and neq s fragments are linked with each other is provided in the form of a precursor of neq dna polymerase.
Research & Business Foundation Sungkyunkwan University

Method for preparing zinc-histidine self-assembly biomimetric complex, zinc-histidine self-assembly complex prepared by said method, and reducing carbon dioxide using said zinc-histidine self-assembly complex

Method for preparing zinc-histidine self-assembly biomimetic complex activating reaction to convert carbon dioxide into bicarbonate ion, zinc-histidine self-assembly biomimetic complex by preparation method, and method for reducing carbon dioxide using zinc-histidine self-assembly biomimetic complex. The preparation includes: mixing l-histidine and p-toluene sulfonic acid in first organic solvent to form first mixed solution and recrystallizing first mixed solution with ethyl ether to prepare first mixed substance: mixing first mixed substance with azelaic acid in second organic solvent to form second mixed substance containing imidazole and amide groups; mixing second mixed substance with naoh and hcl in third organic solvent to form third mixed solution and recrystallizing third mixed solution with ethyl ether to prepare third mixed substance having amphiphilic characteristic: and mixing third mixed substance with aqueous solution of zinc precursor and causing self-assembly to prepare zinc-containing self-assembly biomimetic complex..
Industry-academic Cooperation Foundation Yonsei University

Pharmaceutical formulation for a therapeutic antibody

The present invention relates to pharmaceutical formulations for a therapeutical antibody, preferably an igg, said formulation comprising at least acetate/acidic acid, arginine, and trehalose. In addition, the present invention relates to pharmaceutical formulations for a therapeutical antibody, preferably an igg, said formulation comprising at least histidine, mannitol and/or succinate and trehalose..
Boehringer Ingelheim International Gmbh

Herpesvirus compositions and related methods

The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compositions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization..
Sanofi Pasteur Biologics, Llc

Therapeutic agent, treatment method and inspection diseases caused by activation or neutrophils

The present invention provides a therapeutic agent, a treatment method and an inspection method for diseases caused by activation of neutrophils. More specifically, the invention relates to a neutrophil activation regulator which comprising a histidine-rich glycoprotein (hrg) as an active ingredient, and provides a therapeutic agent for diseases caused by neutrophil activation comprising the neutrophil activation regulator, a treatment method for diseases caused by neutrophil activation, and further an inspection method for diseases caused by neutrophil activation.
National University Corporation Okayama University

Composition for improving or promoting hair growth containing, as active ingredients, photosensitizer irradiated with light and peptide, and method using same

The present invention relates to a composition for improving or promoting hair growth, which contains, as an active ingredient, a photosensitizer-peptide conjugate, and to a method for screening for the hair growth promoter using the active ingredients. Ala, which is the photosensitizer of the present invention, is preferably activated by led radiation, and more preferably activated by radiation having a long wavelength of 650 to 675 nm.
Gwangju Institute Of Science And Technology

Radiation sterilization-resistant protein composition

A protein composition which comprises a mixture of glycine, phenylalanine and histidine and/or a cellulose ether derivative as an additive and has resistance to radiation sterilization.. .

Thermal treatment process for tobacco materials

A method of preparing a tobacco material for use in a smoking article is provided, including (i) mixing a tobacco material, water, and an additive selected from the group consisting of lysine, glycine, histidine, alanine, methionine, glutamic acid, aspartic acid, proline, phenylalanine, valine, arginine, di- and trivalent cations, asparaginase, saccharides, phenolic compounds, reducing agents, compounds having a free thiol group, oxidizing agents, oxidation catalysts, plant extracts, and combinations thereof; (ii) heating the mixture; and (iii) incorporating the heat-treated mixture into a smoking article as a smokable material. A smoking article in the form of a cigarette is also provided that includes a tobacco material pre-treated to inhibit reaction of asparagine to form acrylamide in mainstream smoke.
R. J. Reynolds Tobacco Company

Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same

A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.
Regeneron Pharmaceuticals, Inc.

Biomedical composition

The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or c4-c20 alkane, wherein the modified histidine and the polymer or c4-c20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or c4-c20 alkane is about 0-40%.. .
Industrial Technology Research Institute

Adapter molecule capable of reversibly equipping a fusion protein carrying an oligohistidine affinity tag with a further affinity tag and methods of using the same

Disclosed is a bifunctional adapter molecule comprising two binding moieties a and b, the adapter molecule being capable of reversibly equipping a fusion protein carrying an oligohistidine affinity tag with a further affinity tag, wherein the binding moiety a comprises at least two chelating groups k, wherein each chelating group is capable of binding to a transition metal ion, thereby rendering moiety a capable of binding to an oligohistidine affinity tag, and the binding moiety b is an affinity tag other than an oligohistidine tag.. .
Iba Gmbh

Highly concentrated pharmaceutical formulations

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-cd20 antibody, such as e.g. Rituximab, ocrelizumab, or humab<cd20>, or a mixture of such antibody molecules for subcutaneous injection.
Genentech, Inc.

Affinity chromatography matrix

The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal protein a (e, d, a, b, c) or protein z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to h18 of the b domain of protein a or of protein z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to h18 of the b domain of protein a or of protein z is not serine, threonine or lysine.. .
Ge Healthcare Bio-sciences Ab

Short antimicrobial lipopeptides

Disclosed are peptides having biological and therapeutic activity. Particularly disclosed are lipidated di- or tri-peptides analogs of kpv or kdpt that exhibit antimicrobial activity.
Helix Biomedix Inc.

Neisseria meningitidis compositions and methods thereof

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in seq id no: 1 and a second polypeptide having the sequence set forth in seq id no: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in seq id no: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in seq id no: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mm histidine, and about 150 mm sodium chloride.
Pfizer Inc.

Stable antibody compositions and methods of stabilizing same

The invention provides compositions and methods for inhibiting fractionation of immunoglobulins comprising a lambda light chain based on the observation that iron, in the presence of histidine, results in increased fragmentation of a recombinant fully human igg molecule containing a lambda light chain due to cleavage in the hinge region. The invention further provides an aqueous pharmaceutical formulation comprising an antibody, or antigen-binding portion thereof, that binds the p40 subunit of il-12/il-23 and a buffer system comprising histidine, wherein the formulation has enhanced stability, including enhanced resistance to fragmentation..
Abbvie, Inc.

Compositions and methods for analyzing histidine phosphorylation

A peptide is disclosed of the general structure: z—w—y, wherein z and y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and w is a non-hydrolyzable phis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies.
Sanofi

Recombinant lentiviral vector preparation

Herein is provided a recombinant lentiviral vector preparation, in which the preparation comprises: a) an effective dose of the recombinant lentiviral vector; b) a histidine hydrochloride buffer for keeping a ph value of the preparation in the range of 6.0-8.0; and c) a carbohydrate.. .
Beijing Solobio Genetechnology Company Ltd.

Abiotic and biotic stress tolerance peptides and polynucleotides, and compositions and methods comprising them

X is an amino acid chosen from alanine (a), cysteine (c), aspartic acid (d), glutamic acid (e), phenylalanine (f), glycine (g), histidine (h), isoleucine (i), lysine (k), leucine (l), methionine (m), asparagine (n), proline (p), glutamine (q), arginine (r), serine (s), threonine (t), valine (v), tryptophan (w), or tyrosine (y); (c) growing the plant to produce developed seeds from the plant comprising defenses induced by the defense activators.. .

Composition, method and kit for obtaining purified recombinant proteins

Compositions relating to a combination of two types of separation matrix; and to variant host cells which contain at least one essential host protein that is fused to an affinity binding tag or has been mutated to replace at least two of a plurality of histidines or basic amino acids are provided. Methods are also provided that relate to isolating a recombinant protein from a lysate..
New England Biolabs, Inc.

Anti-tumor aqueous solution, anti-cancer agent, and methods for producing said aqueous solution and said anti-cancer agent

An object of the present invention is to provide an antitumor aqueous solution and an anticancer agent, both of which can kill cancer cells while having virtually no effects on normal cells, and to provide methods for producing the antitumor aqueous solution and the anticancer agent. The method of the invention for producing an antitumor aqueous solution for killing cancer cells includes an aqueous solution preparation step of preparing an aqueous solution through addition, to water, of a solute containing at least one of disodium hydrogen phosphate (na2hpo4), sodium hydrogen carbonate (nahco3), l-glutamine, l-histidine, and l-tyrosine disodium dihydrate (l-tyrosine.2na.2h2o); and a plasma irradiation step of irradiating the aqueous solution with atmospheric pressure plasma generated in a plasma generation region by means of a plasma generator..
Nu Eco Engineeering Co., Ltd.

Methods for identifying fragile histidine triad (fhit) interaction and uses thereof

Provided herein are methods and compositions for the diagnosis, prognosis and treatment of a cancer associated disorders using the fhit gene.. .
The Ohio State University

Compositions and methods for analyzing histidine phosphorylation

A peptide is disclosed of the general structure: z—w—y, wherein z and y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and w is a non-hydrolyzable phis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies.
Sanofi



Histidine topics:
  • Amino Acid
  • Amino Acids
  • Genetically
  • Antibodies
  • Immunoglobulin
  • Polypeptide
  • Nucleic Acid
  • Pertuzumab
  • Trastuzumab
  • Mesoporous Silica
  • Hemoglobin
  • Specificity
  • Carrier Molecule
  • Blood Plasma
  • Recombinant


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Histidine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Histidine with additional patents listed. Browse our RSS directory or Search for other possible listings.


    2.5309

    file did exist - 3015

    0 - 1 - 67